Table 1.
Baseline characteristics before propensity score matching.
| Group CLD (n = 44) | Group Non-CLD (n = 143) | P-value | |
|---|---|---|---|
| Age (years)a | 63.5 (51.25–68.5) | 61 (53–67) | 0.333 |
| Sex (%) | 0.708 | ||
| Male | 26 (59.1) | 89 (62.2) | |
| Female | 18 (40.9) | 54 (37.8) | |
| BMI (kg/m2)b | 23.44 (3.11) | 23.01 (2.68) | 0.376 |
| COPD (%) | 3 (6.8) | 7 (4.9) | 0.910 |
| Hypertension (%) | 9 (20.5) | 23 (16.1) | 0.501 |
| Diabetes mellitus (%) | 6 (13.6) | 17 (11.9) | 0.757 |
| Heart failure (%) | 4 (9.1) | 3 (2.1) | 0.092 |
| Smoking (%) | 12 (27.3) | 34 (23.8) | 0.638 |
| ASA | 0.951 | ||
| I–II | 25 (56.8) | 82 (57.3) | |
| III | 19 (43.2) | 61 (42.7) | |
| T stage (%) | 0.504 | ||
| 1–2 | 4 (9.1) | 7 (4.9) | |
| 3–4 | 40 (90.9) | 136 (95.1) | |
| N stage (%) | 0.370 | ||
| 0 | 16 (36.4) | 58 (40.6) | |
| 1 | 20 (45.5) | 49 (34.3) | |
| 2 | 8 (18.2) | 36 (25.2) | |
| Site of primary colorectal cancer (%) | 0.774 | ||
| Right colon | 13 (29.5) | 38 (26.6) | |
| Left colon | 14 (31.8) | 41 (28.7) | |
| Rectum | 17 (38.6) | 64 (44.8) | |
| Neoadjuvant therapy received (%) | 11 (25) | 35 (24.5) | 0.944 |
| Treatment modality (%) | >0.999 | ||
| Laparoscopy | 44 (100) | 141 (98.6) | |
| Conventional open | 0 (0) | 2 (1.4) | |
| Number of liver metastases (%) | 0.781 | ||
| Solitary metastasis | 18 (40.9) | 67 (46.9) | |
| 2 metastases | 13 (29.5) | 37 (25.9) | |
| ≥3 metastases | 13 (29.5) | 39 (27.3) | |
| Maximum size of liver metastasis (cm)a | 2.85 (2.00–4.15) | 2 (1.3–3) | 0.015 |
| Distribution of liver metastases (%) | 0.282 | ||
| Unilobar | 25 (56.8) | 94 (65.7) | |
| Bilobar | 19 (43.2) | 49 (34.3) |
Values in parentheses are percentages, unless indicated otherwise.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CLD, chronic liver disease.
a
Values are median (interquartile range: 25–75th percentile).
b
Values are mean (standard deviation).